首页> 外文期刊>Journal of Pain Research >Single- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminophen
【24h】

Single- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminophen

机译:与速释氢可酮酒石酸氢盐/布洛芬和速释曲马多HCl /对乙酰氨基酚相比,速释/缓释氢可酮酒石酸氢盐/对乙酰氨基酚双相的单剂量和多剂量药代动力学

获取原文
       

摘要

Objective: To characterize the single-dose and steady-state pharmacokinetics (PK) of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (IR/ER HB/APAP), IR HB/ibuprofen, and IR tramadol HCl/APAP.Methods: In this single-center, open-label, randomized, four-period crossover study, healthy participants received four treatments under fasted conditions: 1) a single dose of two IR/ER HB/APAP 7.5/325 mg tablets (15/650 mg total dose) on day 1, followed by two tablets every 12 hours (q12h) beginning on day 3; 2) a single dose of IR HB/ibuprofen 15/400 mg (divided as one 7.5/200 mg tablet at hour 0 and 6), followed by one tablet every 6 hours (q6h) beginning on day 3; 3) a single dose of IR tramadol HCl/APAP 75/650 mg (divided as one 37.5/325 mg tablet at hour 0 and 6), followed by one tablet q6h beginning on day 3; and 4) a single dose of three IR/ER HB/APAP 7.5/325 mg tablets (22.5/975 mg total dose) on day 1, a three-tablet initial dose at 48 hours followed by two-tablet doses q12h beginning on day 3. Hydrocodone and APAP single-dose and steady-state PK were assessed. Adverse events were monitored.Results: The PK analysis was carried out on 29 of 48 enrolled participants who completed all treatment periods. Single-dose hydrocodone exposure was similar for IR/ER HB/APAP 22.5/975 mg and IR HB/ibuprofen 15/400 mg; time to maximum observed plasma concentration was shorter and half-life was longer for IR/ER HB/APAP (22.5/975 mg and 15/650 mg) vs IR HB/ibuprofen. Single-dose APAP exposure was similar for IR/ER HB/APAP 15/650 mg and IR tramadol HCl/APAP 75/650 mg. Steady-state hydrocodone and APAP exposures were similar between treatments. Adverse events were similar for each treatment and typical of low-dose combination opioid analgesics. With dosing q12h, IR/ER HB/APAP had half as many concentration peaks and troughs as the comparators treated q6h.Conclusion: With dosing q12h, IR/ER HB/APAP provided similar peak and total steady-state hydrocodone and APAP exposure vs IR comparators.
机译:目的:表征双相立即释放/延长释放氢可酮酒石酸氢可酮/对乙酰氨基酚(IR / ER HB / APAP),IR HB /布洛芬和IR曲马多HCl / APAP的单剂量和稳态药代动力学(PK)。方法:在这项单中心,开放标签,随机,四期交叉研究中,健康受试者在禁食条件下接受了四种治疗:1)单剂两个IR / ER HB / APAP 7.5 / 325 mg片剂(15 /在第1天开始服用650毫克总剂量),然后从第3天开始每12小时(q12h)服用2片; 2)单剂IR HB /布洛芬15/400 mg(在第0和6小时分为一片7.5 / 200 mg片剂),然后从第3天开始每6小时(q6h)一次; 3)单剂量IR曲马多HCl / APAP 75/650 mg(在第0和6小时分为一片37.5 / 325 mg片剂),然后从第3天开始每6h服用一片;和4)在第1天单剂3片IR / ER HB / APAP 7.5 / 325毫克片剂(总剂量22.5 / 975毫克),在48小时服用3片初始剂量,然后从第12天开始每2片服用q12h 3.评估了氢可酮和APAP单剂量和稳态PK。结果:对48位已完成所有治疗期的受试者进行了PK分析。 IR / ER HB / APAP 22.5 / 975 mg和IR HB /布洛芬15/400 mg的单剂量氢可酮暴露相似;与IR HB /布洛芬相比,IR / ER HB / APAP(22.5 / 975 mg和15/650 mg)达到最大观察到的血浆浓度的时间更短,半衰期更长。 IR / ER HB / APAP 15/650 mg和IR曲马多HCl / APAP 75/650 mg的单剂量APAP暴露相似。处理之间的稳态氢可酮和APAP暴露相似。每种疗法的不良事件相似,是低剂量联合阿片类镇痛药的典型事件。在第12h给药后,IR / ER HB / APAP的浓度峰和谷值是第6h对照药的一半。结论:在第12h给药后,IR / ER HB / APAP的峰值和总稳态氢可酮和APAP暴露与IR相比比较器。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号